

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

TE-14

RRID:CVCL_3336

Type: Cell Line

Proper Citation

RRID:CVCL_3336

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3336

Proper Citation: RRID:CVCL_3336

Description: Cell line TE-14 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Esophageal squamous cell carcinoma

Defining Citation: [PMID:8509434](#), [PMID:9290701](#), [PMID:15172977](#), [PMID:17804709](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TE-14

Synonyms: TE14

Cross References: CLO:CLO_0051374, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472005, BioSample:SAMN10987745, cancercellines:CVCL_3336, Cell_Model_Passport:SIDM01762, CGH-DB:316-1, Cosmic:983723, Cosmic:1043236, Cosmic:1123331, Cosmic:2698428, DepMap:ACH-000726, GEO:GSM887693, GEO:GSM888786, IARC_TP53:28340, LiGeA:CCLE_147, PharmacDB:TE14_1579_2019, Progenetix:CVCL_3336, RCB:RCB2101, TKG:TKG 0265, Wikidata:Q54972012

ID: CVCL_3336

Record Creation Time: 20220427T221622+0000

Record Last Update: 20260905T182540+0000

Ratings and Alerts

No rating or validation information has been found for TE-14.

No alerts have been found for TE-14.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Saito Y, et al. (2023) Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody. Anticancer research, 43(6), 2425.

Munekage E, et al. (2021) A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia (New York, N.Y.), 23(9), 939.